Amneal Pharmaceuticals, Inc. (AMRX) › Cost of RevenueAmneal Pharmaceuticals, Inc. (AMRX) — Cost of RevenueAnnual figures by period end, from SEC filings.2016-12-31: $420.77M2017-12-31: $507.48M2018-12-31: $938.77M2019-12-31: $1.15B2020-12-31: $1.33B2021-12-31: $1.32B2022-12-31: $1.43B2023-12-31: $1.57B2024-12-31: $1.77B2025-12-31: $1.91B$1.91B2016-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$1.91B+7.4%2026-02-27From 2025-01-012024-12-31$1.77B+12.7%2026-02-27From 2024-01-012023-12-31$1.57B+10.2%2026-02-27From 2023-01-012022-12-31$1.43B+7.8%2025-02-28From 2022-01-012021-12-31$1.32B-0.4%2024-03-14From 2021-01-012020-12-31$1.33B+15.9%2023-03-03From 2020-01-012019-12-31$1.15B+22.2%2022-03-01From 2019-01-012018-12-31$938.77M+85.0%2021-03-01From 2018-01-012017-12-31$507.48M+20.6%2020-03-02From 2017-01-012016-12-31$420.77M—2019-03-01From 2016-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)